NVO — Novo Nordisk A/S

Deep-value report: Novo Nordisk A/S (NVO) — 2026-07-18

Currency convention: operational figures (revenue, profit, EPS, cash flow) are reported in DKK (Danish kroner), the company’s official reporting currency per the 20-F/6-K. The share price, market cap and multiples are in USD (ADR NVO, NYSE). Conversion rate used: …/USD (July 2026 average, source: X-Rates/valutafx). Reference price: … (July 17, 2026, source: stockanalysis.com).

Executive summary

Thesis. Novo Nordisk is the historical leader of the GLP-1 market (Ozempic, Wegovy, Rybelsus) — a franchise with exceptional margins (net margin 33%, ROIC ~38%) and a moat built on patents, manufacturing scale and prescriber relationships. But 2025 was the year the “quality compounder, buy any dip” thesis broke down: the company itself acknowledges in its 20-F that it lost the leading position to Eli Lilly in both Ozempic (diabetes) and Wegovy (obesity) during 2025 (source: NVO 20-F 2026-02-04, Item 4.B); it cut growth guidance three times in six months; it changed CEOs under direct pressure from the majority shareholder (Novo Nordisk Foundation); it announced the layoff of ~9,000 employees (~11% of the workforce); and it completely suspended the share buyback program in the very year the stock fell ~65% from its peak (source: agent research 6-K, TradingNews).

Estimated value. A conservative DCF (growth 4… in the early years, FCF margin normalizing gradually to 25% as the capex supercycle winds down) gives a base value of ~…/share, with a range of … (bear) – … (bull) across the three scenarios. Earnings Power Value (EPV, no growth, using normalized EBIT) gives …-49/share. Both methods anchored in real cash flow converge very close to the current price of … — meaning no real margin of safety in the conservative scenario. Reversion to the historical 5-year multiple (average P/E 30x) would give a much higher value (…+), but that multiple was set during a period of 20%+/year growth with no serious competition — using it as an anchor today would be a methodological error, not a signal of undervaluation.

Verdict. This is NOT yet a “buy without discussion” opportunity despite the massive price decline. The quality of the underlying business remains excellent (ROIC 38%, gross margin 81%, real patent moat through 2031-2032), but the competitive deterioration is confirmed by the company itself, not just market perception, and at the current price there is no sufficient discount to a conservative valuation. The recalculated GBL score is 43.3% (SPECULATIVE), significantly below the tracker score (63.3%, INTERESTING) — see the final section for the explanation of the divergence.